GLAUKOS Corp (GKOS) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, GLAUKOS Corp's filing signal continuing positive.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company specializing in novel, dropless therapies for glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent family of products, launched in 2012, and in 2024, began commercializing iDose TR, a sustained-release intracameral implant for glaucoma. Glaukos also offers bio-activated pharmaceutical therapies for corneal disorders, such as its iLink platform for keratoconus. The company's strategy focuses on advancing the standard of care through a robust pipeline of innovative, dropless platform technologies aimed at improving patient outcomes for chronic eye diseases.

Net sales are primarily generated from the iStent family of products, iDose TR, and Photrexa therapies, which together accounted for approximately 83% of net sales in 2025. The iLink therapies and associated products contributed the remaining 17% of net sales.